H.C. Wainwright lowered the firm’s price target on Entera Bio (ENTX) to $9 from $10 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTX:
- Entera Bio Announces $10 Million Private Placement Financing
- Entera Bio Reports 2025 Results, Advances Oral Osteoporosis Pipeline
- Entera May Be the 1st Winner of FDA’s New Framework Redefining the Multi Billion Dollar Osteoporosis Market
- Entera Takes Final Step Towards Phase 3, Accelerating Timeline for First Oral Anabolic Osteoporosis Therapy
- Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)